Format

Send to:

Choose Destination
See comment in PubMed Commons below
Hepatology. 2012 May;55(5):1620-8. doi: 10.1002/hep.25653.

Review and management of drug interactions with boceprevir and telaprevir.

Author information

  • 1Schools of Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA. jennifer.kiser@ucdenver.edu

Abstract

Boceprevir (BOC) and telaprevir (TPV), when added to pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the rates of sustained virologic response in treatment-naïve persons to approximately 70%. Though these agents represent an important advance in the treatment of chronic HCV, they present new treatment challenges to the hepatology community. BOC and TPV are both substrates and inhibitors of the hepatic enzyme, cytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes these agents to many drug interactions. Identification and appropriate management of potential drug interactions with TPV and BOC is critical for optimizing therapeutic outcomes during hepatitis C treatment. This review highlights the pharmacologic characteristics and drug-interaction potential of BOC and TPV and provides guidance on the management of drug interactions with these agents.

Copyright © 2012 American Association for the Study of Liver Diseases.

PMID:
22331658
[PubMed - indexed for MEDLINE]
PMCID:
PMC3345276
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk